Alterity Therapeutics Ltd (PRNAF) — 6-K Filings

6-K Filings (50)

• Alterity Therapeutics Files 6-K, Incorporates Director's Interest Notice — Nov 24, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on November 24, 2025, to incorporate by reference into several of its Registration Statements on Form S-8 and Form F
• 6-K Filing — Nov 21, 2025
• 6-K Filing — Nov 13, 2025
• Alterity Therapeutics to Present at Bell Conference — Nov 12, 2025 Risk: low
  Alterity Therapeutics Ltd. announced on November 12, 2025, that it will present at the Bell Conference. This filing incorporates by reference the 6-K report int
• 6-K Filing — Nov 10, 2025
• Alterity Therapeutics Files 6-K, Incorporates Activities Report — Oct 31, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on October 30, 2025, incorporating by reference its Quarterly Activities/Appendix 4C report. This filing is relat
• Alterity Therapeutics Files 6-K for AGM Notice — Oct 21, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on October 21, 2025, to report its Notice of Annual General Meeting as Exhibit 99.1. The company, formerly known
• Alterity Therapeutics Files 6-K on Holding Change — Oct 15, 2025 Risk: medium
  Alterity Therapeutics Limited filed a Form 6-K on October 15, 2025, reporting a change in substantial holding. This filing is incorporated by reference into sev
• Alterity Therapeutics Presents Positive ATH434 Data — Oct 9, 2025 Risk: medium
  Alterity Therapeutics Ltd. filed a Form 6-K on October 9, 2025, to incorporate by reference into several of its SEC registration statements. The filing includes
• Alterity Therapeutics Files 6-K, Incorporates Presentations — Oct 2, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on October 2, 2025, to incorporate by reference into several of its Registration Statements on Form S-8 and Form F-3
• Alterity Therapeutics Ltd. Announces AGM Date — Sep 23, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on September 23, 2025, to report on the date of its Annual General Meeting (AGM) and the closing date for director n
• Alterity Therapeutics Files 6-K on Substantial Holding Change — Sep 17, 2025 Risk: medium
  Alterity Therapeutics Limited filed a Form 6-K on September 17, 2025, to report a change in substantial holding. This filing is incorporated by reference into s
• Alterity Therapeutics Files 6-K, Incorporates by Reference — Sep 15, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on September 15, 2025, to incorporate by reference into its existing Registration Statements on Form S-8 and Form F-
• Alterity Therapeutics Raises $20M in Strategic Placement — Sep 8, 2025 Risk: medium
  Alterity Therapeutics Ltd. announced on September 8, 2025, that it has raised $20.0 million through a strategic placement. This filing incorporates the announce
• Alterity Therapeutics Trading Halt for Capital Raise — Sep 4, 2025 Risk: medium
  Alterity Therapeutics Ltd. announced a trading halt on September 4, 2025, pending an announcement regarding a capital raising. The company, formerly known as Pr
• Alterity Therapeutics Files 6-K, Incorporates into S-8/F-3 Filings — Sep 2, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on September 2, 2025, for the month of August 2025. This report is being incorporated by reference into several of t
• Alterity Therapeutics Files 6-K, Incorporates into Registration Statements — Aug 22, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on August 22, 2025, to incorporate by reference into several of its existing Registration Statements on Form S-8 and
• Alterity Therapeutics Files 6-K on Unquoted Securities — Aug 15, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on August 15, 2025, to report information regarding unquoted securities. This filing is incorporated by reference
• Alterity Therapeutics Files 6-K, Incorporates by Reference — Aug 4, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on August 4, 2025, to incorporate by reference into several of its existing Registration Statements on Form S-8 a
• Alterity Therapeutics Files 6-K with Updated Corporate Presentation — Jul 31, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on July 31, 2025, to incorporate by reference an updated Corporate Presentation into its existing Registration St
• Alterity Therapeutics Files 6-K, Incorporates Cash Flow Report — Jul 30, 2025 Risk: medium
  Alterity Therapeutics Ltd. filed a Form 6-K on July 30, 2025, incorporating by reference its Quarterly Activities/Appendix 4C Cash Flow Report. This filing is r
• Alterity Therapeutics Files 6-K on Substantial Holding Change — Jul 28, 2025 Risk: medium
  Alterity Therapeutics Limited filed a Form 6-K on July 28, 2025, to report a change in substantial holding. The filing is incorporated by reference into several
• Alterity Therapeutics Files 6-K with BioMUSE Study Publication — Jul 24, 2025 Risk: medium
  Alterity Therapeutics Ltd. filed a Form 6-K on July 24, 2025, incorporating a peer-reviewed publication regarding a novel MRI endpoint from their bioMUSE study.
• Alterity Therapeutics Files 6-K, Incorporates into Registration Statements — Jul 21, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on July 21, 2025, to incorporate by reference into its existing Registration Statements on Form S-8 and Form F-3.
• Alterity Therapeutics Files 6-K, Incorporates into Registrations — Jul 17, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on July 17, 2025, incorporating information into its existing Registration Statements on Form S-8 and Form F-3. The
• Alterity Therapeutics Files 6-K with ASX Price Query Response — Jul 14, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on July 14, 2025, incorporating by reference into several of its existing SEC registration statements. The filing in
• Alterity Therapeutics Files 6-K on Substantial Holding Change — Jul 7, 2025 Risk: medium
  Alterity Therapeutics Ltd. filed a Form 6-K on July 7, 2025, to report a change in substantial holding. This filing is incorporated by reference into several of
• Alterity Therapeutics Files 6-K, Incorporates by Reference — Jul 3, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on July 3, 2025, to incorporate by reference into several of its existing Registration Statements on Form S-8 and
• Alterity Therapeutics Files 6-K on Security Cessation — Jun 30, 2025 Risk: medium
  Alterity Therapeutics Limited filed a Form 6-K on June 30, 2025, reporting a notification of cessation of securities for ATH. This filing is incorporated by ref
• Alterity Therapeutics CEO to Update on ATH434 — Jun 23, 2025 Risk: medium
  Alterity Therapeutics Limited filed a Form 6-K on June 23, 2025, to incorporate by reference into its existing Registration Statements on Form S-8 and Form F-3.
• Alterity Therapeutics Files 6-K on Shareholder Holdings — May 23, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on May 23, 2025, to report a change in substantial holding. This filing is incorporated by reference into several
• Alterity Therapeutics Featured at International MSA Congress — May 12, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on May 12, 2025, to report its activities for May 2025. The filing incorporates by reference into several of its S-8
• Alterity Therapeutics to Present Phase 2 Data at MSA Congress — May 7, 2025 Risk: medium
  Alterity Therapeutics Ltd. announced on May 7, 2025, that its Phase 2 data for its Alzheimer's drug candidate will be presented at the MSA Congress. This filing
• Alterity Therapeutics Gets FDA Fast Track for ATH434 — May 5, 2025 Risk: medium
  Alterity Therapeutics Ltd. announced on May 5, 2025, that its lead drug candidate, ATH434, has received U.S. FDA Fast Track Designation for the treatment of Mul
• Alterity Therapeutics Files 6-K, Incorporates Cash Flow Report — Apr 30, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on April 30, 2025, incorporating by reference its Quarterly Activities/Appendix 4C Cash Flow Report. This filing is
• Alterity Therapeutics Files 6-K on Director Interest Change — Apr 29, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on April 29, 2025, to report a change in a director's interest. This filing is incorporated by reference into severa
• Alterity Therapeutics Files 6-K, Includes Phase 2 Presentation — Apr 28, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on April 28, 2025, to report its activities for April 2025. This filing incorporates by reference into several of th
• Alterity Therapeutics Files Updated Corporate Presentation — Apr 22, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on April 22, 2025, to incorporate by reference an updated Corporate Presentation. This filing is being included i
• Alterity Therapeutics Files 6-K with Options Prospectus — Apr 17, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on April 17, 2025, to incorporate by reference into its existing Registration Statements on Form S-8 and Form F-3. T
• Alterity Therapeutics Files Director Interest Notice — Apr 10, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on April 10, 2025, incorporating by reference a Change of Director's Interest Notice. This filing is related to thei
• Alterity Therapeutics Files 6-K, Incorporates by Reference — Apr 9, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on April 9, 2025, to incorporate by reference into its existing Registration Statements on Form S-8 and Form F-3. Th
• Alterity Therapeutics Files 6-K on Substantial Holding Change — Apr 8, 2025 Risk: medium
  Alterity Therapeutics Limited filed a Form 6-K on April 8, 2025, to report a change in substantial holding. This filing is incorporated by reference into severa
• Alterity Therapeutics Files 6-K, Incorporates into Registrations — Apr 7, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on April 7, 2025, to incorporate by reference into its existing Registration Statements on Form S-8 and Form F-3. Th
• Alterity Therapeutics to Present ATH434 Trial Data at AAN — Apr 3, 2025 Risk: medium
  Alterity Therapeutics Ltd. announced on April 3, 2025, that it will deliver an oral presentation of its ATH434 trial data at the American Academy of Neurology (
• Alterity Therapeutics Files 6-K with Meeting Results — Mar 31, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on March 31, 2025, reporting the results of a meeting. This filing is incorporated by reference into several of t
• Alterity Therapeutics Completes Last Patient Visit in Open-Label Trial — Mar 27, 2025 Risk: medium
  Alterity Therapeutics Ltd. announced on March 27, 2025, that it has completed the last patient visit for its open-label trial. This marks a significant step in
• Alterity Therapeutics Files 6-K, Reports Substantial Holder Change — Mar 25, 2025 Risk: medium
  Alterity Therapeutics Ltd. filed a Form 6-K on March 25, 2025, to report its activities for March 2025. This filing includes an exhibit titled 'Ceasing to be a
• Alterity Therapeutics Files 6-K, Incorporates into Registrations — Mar 14, 2025 Risk: low
  Alterity Therapeutics Limited filed a Form 6-K on March 14, 2025, to incorporate by reference into its existing Registration Statements on Form S-8 and Form F-3
• Alterity Therapeutics Files 6-K, Incorporates into Registrations — Mar 14, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on March 14, 2025, to report its activities for the month of March 2025. This filing incorporates by reference infor
• Alterity Therapeutics Files 6-K, Incorporates into Registration Statements — Feb 28, 2025 Risk: low
  Alterity Therapeutics Ltd. filed a Form 6-K on February 28, 2025, to report on activities for the month of February 2025. This filing incorporates by reference

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX